Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses.

Patrick Dmc KatotoMireille Am KakubuJacques L TamuziAmanda S BrandAdaeze AyukLiliane N ByamunguCharles Shey WiysongeGlenda Gray

Published in: Expert review of vaccines (2023)

This study provides preliminary evidence that the BNT162b2 vaccine is safe and effective in immunocompromised adolescents and young adults, but with low to moderate evidence quality due to bias risk. The study calls for improved methodological quality in studies involving specific populations.

Keyphrases

sars cov
meta analyses
randomized controlled trial
intensive care unit
quality improvement
high intensity
respiratory failure
respiratory syndrome coronavirus
extracorporeal membrane oxygenation